CA
ALT icon

Clearstead Advisors’s Altimmune ALT Stock Holding History

Clearstead Advisors’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$998 Buy
328
+288
+720% +$860 ﹤0.01% 2692
2026
Q1 		$122 Hold
40
– – ﹤0.01% 2195
2025
Q4 		$143 Buy
+40
New +$174 ﹤0.01% 2465

Other funds holding ALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
BWCS
Beirne Wealth Consulting Services Shelton, Connecticut $503M AUM 27.98% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BWM
Brown Wealth Management Naperville, Illinois $447M AUM 16.94% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Clearstead Advisors's ALT Position: Q2 2026 in Review

Clearstead Advisors increased its Altimmune (ALT) stake by 720% in Q2 2026, buying an estimated $860 and bringing the position to 328 shares worth $998. The position accounts for ﹤0.01% of the portfolio, ranked #2692.

Clearstead Advisors first reported a position in ALT in Q4 2025 and has held it in 3 quarters since. 72 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

  • Clearstead Advisors held 328 shares of Altimmune worth $998 as of Q2 2026.
  • Clearstead Advisors bought 288 Altimmune shares in Q2 2026, an estimated $860.
  • Altimmune made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2692 holding.
  • Clearstead Advisors first reported a position in Altimmune in Q4 2025 and has held it in 3 quarters since.
  • 72 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.